ArticleUrology case reports2024

AKR1C3-negative high-risk metastatic castration-sensitive prostate cancer has long-term response to first-line treatment with abiraterone: Four case reports.

Tsuyoshi Yoshizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.